Equillium Inc (EQ)

$1.87 -0.12 (-6.03%)
Market Cap 118.41M
Revenue (ttm) 41.10M
Net Income (ttm) -8.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -19.64%
Debt to Equity Ratio 0.00
Volume 691,300
Avg Vol 10,012,729
Day's Range N/A - N/A
Shares Out 59.50M
Stochastic %K 39%
Beta 1.58
Analysts Sell
Price Target $2.50

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 240 1200
Address:
2223 Avenida De La Playa, Suite 105, La Jolla, United States
algo888
algo888 Sep. 12 at 7:06 PM
$EQ Pathetic scalping from 1.92 - 2.02 range ...
0 · Reply
algo888
algo888 Sep. 12 at 6:01 PM
$EQ Looking good babe!!!
0 · Reply
Ycapital
Ycapital Sep. 12 at 5:32 PM
$EQ Funny you brag about $PRTS while pumping EQ. Check their 10-Q: cash <6m, S-3 filed for dilution, runway ends 2025. Partners in $PRTS are locked only win if PPS grows. Succes with pump & dumps chasing. 🍀
0 · Reply
algo888
algo888 Sep. 12 at 4:49 PM
$EQ Slap the ask... super thin to 2.35 - 2.50 range; no sell pressure
0 · Reply
algo888
algo888 Sep. 12 at 4:32 PM
$EQ huge Buys moving in .... Spank it
0 · Reply
ApexTwin
ApexTwin Sep. 12 at 4:13 PM
$EQ $BTC.X $IONQ HUGE parabolic breakout into the $3.00-$3.35 range is about to happen anytime now from this $1.94 level. EQ is about to take off like a rocket.
0 · Reply
algo888
algo888 Sep. 12 at 3:09 PM
$EQ 45 min super tight trading range ..
0 · Reply
algo888
algo888 Sep. 12 at 3:04 PM
$EQ explosive negative Bullish divergence consolidation on low volume, no selling pressure....
0 · Reply
algo888
algo888 Sep. 12 at 2:57 PM
$EQ Oversold on the 30 min all the way to 8 Hr wow!!! Explosive Daily and Weekly
0 · Reply
algo888
algo888 Sep. 12 at 2:49 PM
$EQ price above all the moving averages 4 9 13 20 50 200 and weekly all it needs is volume...
0 · Reply
Latest News on EQ
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2025, 4:05 PM EDT - 9 days ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 29, 2025, 4:03 PM EDT - 14 days ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

Aug 28, 2025, 5:35 PM EDT - 15 days ago

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 11, 2025, 8:30 AM EDT - 4 weeks ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Aug 4, 2025, 8:30 AM EDT - 5 weeks ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025, 8:00 AM EDT - 4 months ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025, 8:00 AM EDT - 4 months ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium Announces Feedback from the U.S. Food and Drug Administration

Apr 24, 2025, 9:00 AM EDT - 5 months ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 11:16 AM EDT - 6 months ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Feb 6, 2025, 8:00 AM EST - 7 months ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 4:01 PM EST - 10 months ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 10 months ago

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Nov 12, 2024, 8:00 AM EST - 10 months ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 31, 2024, 7:00 AM EDT - 11 months ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 18, 2024, 1:57 PM EDT - 1 year ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to Participate in Upcoming Investor Conferences

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Equillium to Participate in Upcoming Investor Conferences

Equillium to be included in the Russell Microcap® Index

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Equillium to be included in the Russell Microcap® Index

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Dec 21, 2023, 8:00 AM EST - 1 year ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 13, 2023, 9:00 AM EST - 1 year ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Nov 6, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium to Host Analyst & Investor Day

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Equillium to Host Analyst & Investor Day

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Aug 9, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces $7.5 Million Share Repurchase Program

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Equillium Announces $7.5 Million Share Repurchase Program

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look

May 12, 2023, 4:15 PM EDT - 2 years ago

Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

May 11, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

algo888
algo888 Sep. 12 at 7:06 PM
$EQ Pathetic scalping from 1.92 - 2.02 range ...
0 · Reply
algo888
algo888 Sep. 12 at 6:01 PM
$EQ Looking good babe!!!
0 · Reply
Ycapital
Ycapital Sep. 12 at 5:32 PM
$EQ Funny you brag about $PRTS while pumping EQ. Check their 10-Q: cash <6m, S-3 filed for dilution, runway ends 2025. Partners in $PRTS are locked only win if PPS grows. Succes with pump & dumps chasing. 🍀
0 · Reply
algo888
algo888 Sep. 12 at 4:49 PM
$EQ Slap the ask... super thin to 2.35 - 2.50 range; no sell pressure
0 · Reply
algo888
algo888 Sep. 12 at 4:32 PM
$EQ huge Buys moving in .... Spank it
0 · Reply
ApexTwin
ApexTwin Sep. 12 at 4:13 PM
$EQ $BTC.X $IONQ HUGE parabolic breakout into the $3.00-$3.35 range is about to happen anytime now from this $1.94 level. EQ is about to take off like a rocket.
0 · Reply
algo888
algo888 Sep. 12 at 3:09 PM
$EQ 45 min super tight trading range ..
0 · Reply
algo888
algo888 Sep. 12 at 3:04 PM
$EQ explosive negative Bullish divergence consolidation on low volume, no selling pressure....
0 · Reply
algo888
algo888 Sep. 12 at 2:57 PM
$EQ Oversold on the 30 min all the way to 8 Hr wow!!! Explosive Daily and Weekly
0 · Reply
algo888
algo888 Sep. 12 at 2:49 PM
$EQ price above all the moving averages 4 9 13 20 50 200 and weekly all it needs is volume...
0 · Reply
algo888
algo888 Sep. 12 at 2:43 PM
$EQ all cleared for the retest to 2.35 then a new 52 week high @ 2.50
0 · Reply
algo888
algo888 Sep. 12 at 2:41 PM
$EQ added 3K shares @ 1.99 Thanks Babe
0 · Reply
algo888
algo888 Sep. 11 at 8:24 PM
$EQ 854,084 BUYS or 95% Buying
0 · Reply
algo888
algo888 Sep. 11 at 8:19 PM
$PFSA Im pumping both hard > >>> $EQ $TLPH dont get left behind and cry again
0 · Reply
algo888
algo888 Sep. 11 at 8:16 PM
$EQ Damn... .36 cents away to a new 52 week high breakout!!! Get ready chasers..
0 · Reply
algo888
algo888 Sep. 11 at 8:01 PM
$EQ It was Fake news to free up shares and create panic selling in the last 3 days all the way to the 1.70's 1.80's now @ 2.00 LOL
0 · Reply
apkjiv88
apkjiv88 Sep. 11 at 7:59 PM
$EQ how is this still going up after offering?
0 · Reply
algo888
algo888 Sep. 11 at 7:59 PM
$EQ 2.00 Re-entry = BOOOMAGE!!! wow
0 · Reply
algo888
algo888 Sep. 11 at 7:45 PM
$EQ scalping fools had to resort to dirty tactics putting out Fake news that 52 million shares; more than the entire outstanding shares are dumping???? LMAO
0 · Reply
algo888
algo888 Sep. 11 at 7:39 PM
$EQ first time showing strength towards the closing.... Load it while still quiet below 2.35
0 · Reply
PeterLynch777
PeterLynch777 Sep. 11 at 7:13 PM
$EQ 🧐
0 · Reply
algo888
algo888 Sep. 11 at 7:12 PM
$TLPH $EQ < < < explosive picks
0 · Reply